Isoprostanes inhibit vascular endothelial growth factor-induced endothelial cell migration, tube formation, and cardiac vessel sprouting in vitro, As well as angiogenesis in vivo via activation of the thromboxane A2 receptor: A potential link between oxidative stress and impaired angiogenesis

Circulation Research

Volumn 103, Issue 9, 2008, Pages 1037-1046

  Benndorf, Ralf A ^a   Schwedhelm, Edzard ^a   Gnann, Anke ^a   Taheri, Raihana ^a   Kom, Ghainsom ^a   Didié, Michael ^a   Steenpass, Anna ^a   Ergün, Süleyman ^b   Böger, Rainer H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Angiogenesis; Isoprostanes; Migration; Rho kinase; Thromboxane A2 receptor

Indexed keywords

8 ISO PROSTAGLANDIN A2; 8 ISO PROSTAGLANDIN E2; 8 ISO PROSTAGLANDIN F2ALPHA; ISOPROSTANE DERIVATIVE; SHORT HAIRPIN RNA; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 6 [2 (2 CHLOROPHENYL) 4 (2 HYDROXYPHENYL) 1,3 DIOXAN 5 YL] 4 HEXENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; 8 EPI PROSTAGLANDIN F2ALPHA; 8 ISOPROSTAGLANDIN A2; 8 ISOPROSTAGLANDIN E2; 8-EPI-PROSTAGLANDIN F2ALPHA; 8-ISOPROSTAGLANDIN A2; 8-ISOPROSTAGLANDIN E2; ACTIN; ANGIOGENESIS INHIBITOR; BM 567; DIOXANE DERIVATIVE; DRUG DERIVATIVE; FOCAL ADHESION KINASE 1; HYDRAZINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PROSTAGLANDIN A; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROTEIN KINASE B; PTK2 PROTEIN, HUMAN; SMALL INTERFERING RNA; SULFONYLUREA DERIVATIVE; VASCULOTROPIN A;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CARDIOVASCULAR EFFECT; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; VASCULARIZATION; ANIMAL; APOPTOSIS; CELL CULTURE; CELL MOTION; CHICK EMBRYO; CHORIOALLANTOIS; CORONARY BLOOD VESSEL; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; STRESS FIBER; TISSUE CULTURE TECHNIQUE;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ACTINS; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL MOVEMENT; CELLS, CULTURED; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; CORONARY VESSELS; DINOPROST; DINOPROSTONE; DIOXANES; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FOCAL ADHESION KINASE 1; HUMANS; HYDRAZINES; ISOPROSTANES; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; OXIDATIVE STRESS; PHOSPHORYLATION; PROSTAGLANDINS A; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; RNA INTERFERENCE; RNA, SMALL INTERFERING; STRESS FIBERS; SULFONYLUREA COMPOUNDS; TISSUE CULTURE TECHNIQUES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55449120824     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.184036     Document Type: Article

References (36)

1. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.
2. Richter C, Gogvadze V, Laffranchi R, Schlapbach R, Schweizer M, Suter M, Walter P, Yaffee M. Oxidants in mitochondria: from physiology to diseases. Biochim Biophys Acta. 1995;1271:67-74.
3. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA. 1990;87:9383-9387.
4. Montuschi P, Barnes P, Roberts LJ II. Insights into oxidative stress: the isoprostanes. Curr Med Chem. 2007;14:703-717.
5. Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brummer J, Gutzki FM, Berger J, Frolich JC, Boger RH. Urinary 8-iso-prostaglandin F2a as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation. 2004;109:843-848.
6. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ II. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med. 1995;332:1198-1203.
7. Davi G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F, Cipollone F, Bon GB, Ciabattoni G, Patrono C. In vivo formation of 8-Epi-prostaglandin F2 a is increased in hypercholesterolemia. Arte-rioscler Thromb Vasc Biol. 1997;17:3230-3235.
8. Reilly MP, Delanty N, Roy L, Rokach J, Callaghan PO, Crean P, Lawson JA, FitzGerald GA. Increased formation of the isoprostanes IPF2a-I and 8-epi-prostaglandin F2a in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation. 1997; 96:3314-3320.
9. Laffer CL, Bolterman RJ, Romero JC, Elijovich F. Effect of salt on isoprostanes in salt-sensitive essential hypertension. Hypertension. 2006; 47:434-440.
10. Il?yasova D, Morrow JD, Wagenknecht LE. Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes. Obes Res. 2005;13: 1638-1644.
11. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C. In vivo formation of 8-iso-prostaglandin f2a and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999;99:224-229.
12. Fukuda K, Davies SS, Nakajima T, Ong BH, Kupershmidt S, Fessel J, Amarnath V, Anderson ME, Boyden PA, Viswanathan PC, Roberts LJ II, Balser JR. Oxidative mediated lipid peroxidation recapitulates proar-rhythmic effects on cardiac sodium channels. Circ Res. 2005;97: 1262-1269.
13. Schwedhelm E, Benndorf RA, Boger RH, Tsikas D. Mass spectrometric analysis of F2-isoprostanes: markers and mediators in human disease. Curr Pharm Anal. 2007;1:39-51.
14. Hou X, Roberts LJ II, Gobeil F Jr, Taber D, Kanai K, Abran D, Brault S, Checchin D, Sennlaub F, Lachapelle P, Varma D, Chemtob S. Isomer-specific contractile effects of a series of synthetic F2-isoprostanes on retinal and cerebral microvasculature. Free Radic Biol Med. 2004;36: 163-172.
15. Tang M, Cyrus T, Yao Y, Vocun L, Pratico D. Involvement of thromboxane receptor in the proatherogenic effect of isoprostane F2a-III: evidence from apolipoprotein E-and LDL receptor-deficient mice. Circulation. 2005;112:2867-2874.
16. Folco G, Granstrom E, Kindahl H. Albumin stabilizes thromboxane A2. FEBS Lett. 1977;82:321-324.
17. Schaper W, Ito WD. Molecular mechanisms of coronary collateral vessel growth. Circ Res. 1996;79:911-919.
18. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med. 2000;342:626-633.
19. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005; 438:932-936.
20. Ciuffetti G, Schillaci G, Innocente S, Lombardini R, Pasqualini L, Notaristefano S, Mannarino E. Capillary rarefaction and abnormal cardiovascular reactivity in hypertension. J Hypertens. 2003;21:2297-2303.
21. Gao Y, Yokota R, Tang S, Ashton AW, Ware JA. Reversal of angio-genesis in vitro, induction of apoptosis, and inhibition of AKT phosphor-ylation in endothelial cells by thromboxane A(2). Circ Res. 2000;87: 739-745.
22. Ashton AW, Ware JA. Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration. Circ Res. 2004;95:372-379.
23. Benndorf R, Boger RH, Ergun S, Steenpass A, Wieland T. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. Circ Res. 2003;93:438-447.
24. Kiefer FN, Munk VC, Humar R, Dieterle T, Landmann L, Battegay EJ. A versatile in vitro assay for investigating angiogenesis of the heart. Exp Cell Res. 2004;300:272-282.
25. Iruela-Arispe ML, Lane TF, Redmond D, Reilly M, Bolender RP, Kavanagh TJ, Sage EH. Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo. Mol Biol Cell. 1995;6:327-343.
26. Ergün S, Kilik N, Ziegeler G, Hansen A, Nollau P, Götze J, Wurmbach JH, Horst A, Weil J, Fernando M, Wagener C. CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor. Mol Cell. 2000;5:311-320.
27. Wojciak-Stothard B, Torondel B, Tsang LY, Fleming I, Fisslthaler B, Leiper JM, Vallance P. The ADMA/DDAH pathway is a critical regulator of endothelial cell motility. J Cell Sci. 2007;120:929-942.
28. Zachary I. Signal transduction in angiogenesis. EXS. 2005;94:267-300.
29. Milne GL, Sanchez SC, Musiek ES, Morrow JD. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc. 2007;2: 221-226.
30. Pal S, Wu J, Murray JK, Gellman SH, Wozniak MA, Keely PJ, Boyer ME, Gomez TM, Hasso SM, Fallon JF, Bresnick EH. An antiangiogenic neurokinin-B/ thromboxane A2 regulatory axis. J Cell Biol. 2006;174: 1047-1058.
31. Nie D, Lamberti M, Zacharek A, Li L, Szekeres K, Tang K, Chen Y, Honn KV. Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun. 2000;267:245-251. (Pubitemid 30072537)
32. Brault S, Martinez-Bermudez AK, Marrache AM, Gobeil F Jr, Hou X, Beauchamp M, Quiniou C, Almazan G, Lachance C, Roberts J II, Varma DR, Chemtob S. Selective neuromicrovascular endothelial cell death by 8-Iso-prostaglandin F2alpha: possible role in ischemic brain injury. Stroke. 2003;34:776-782.
33. Belhassen L, Pelle G, Dubois-Rande JL, Adnot S. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol. 2003;41:1198-1204.
34. Wikström K, Kavanagh DJ, Reid HM, Kinsella BT. Differential regulation of RhoA-mediated signaling by the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor: independent modulation of TPalpha signaling by prostacyclin and nitric oxide. Cell Signal. 2008;20: 1497-1512.
35. Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis. Circ Res. 2007;100:782-794.
36. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation. 2002;106:57-62.